Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sovleplenib (HMPL-523) in Healthy Chinese Subjects
NCT05318820Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sovleplenib in immune thrombocytopenia (ITP) (3 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: maximum plasma concentration, time to maximum plasma concentration and 3 more. Started Jun 2022; status: completed.
02
Drugs
sovleplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05318820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318820.